Menu
  • Join
  • Login
  • Contact
 

Search abstracts


NIVOLUMAB-INDUCED FULMINANT TYPE 1 DIABETES

  • At: 2019 FIP Congress in AbuDhabi (United Arab Emirates)
  • Type: Poster
  • By: MORGADO, Manuel (University of Beira Interior, Health Science Faculty, Portugal)
  • Co-author(s): Carolina Lopes: Health Science Faculty, University of Beira Interior, Covilhã, Portugal
    Ema Paulino: Portuguese Pharmaceutical Society, Lisbon, Portugal
    Sandra Morgado: Pharmaceutical Services, University Hospital Center of Cova da Beira, Covilhã, Portugal
    Manuel Morgado: Pharmaceutical Services, University Hospital Center of Cova da Beira, Covilhã, Portugal;Health Science Faculty, University of Beira Interior, Covilhã, Portugal;School of Health Sciences, Polytechnic Institute of Guarda, Guarda, Portugal
  • Abstract:

    Background

    Nivolumab is an immune checkpoint inhibitor (ICI) that binds and blocks the activation of PD-1’s receptor, reactivating T cells and cell-mediated immune responses. Fulminant type 1 diabetes (FD) is an immune endocrinopathy resulting from a violent immune attack which leads to complete destruction of pancreatic β-cells. FD can happen as..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 21 September 2019

FIP Congresses